The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study
Open accessAbstract
Context: Randomized controlled trials evaluating real-time continuous glucose monitoring (RT-CGM) patients with type 1 diabetes (T1D) show improved glycemic control, but limited data are available on real-world use. Objective: To assess impact of RT-CGM in real-world settings on glycemic control, hospital admissions, work absenteeism, and quality of life (QOL). Design: Prospective, observational, multicenter, cohort study. Participants: A total of 515 adults with T1D on continuous subcutaneous insulin infusion (CSII) therapy starting in the Belgian RT-CGM reimbursement program. Intervention: Initiation of RT-CGM reimbursement. Main Outcome Measure: Hemoglobin A1c (HbA1c) evolution from baseline to 12 months. Results: Between September 1, 2014, and December 31, 2016, 515 adults entered the reimbursement system. Over this period, 417 (81%) patients used RT-CGM for at least 12 months. Baseline HbA1c was 7.7 ± 0.9% (61 ± 9.8 mmol/mol) and decreased to 7.4 ± 0.8% (57 ± 8.7 mmol/mol) at 12 months (P < 0.0001). Subjects who started RT-CGM because of insufficient glycemic control showed stronger decrease in HbA1c at 4, 8, and 12 months compared with patients who started because of hypoglycemia or pregnancy. In the year preceding reimbursement, 16% of patients were hospitalized for severe hypoglycemia or ketoacidosis in contrast to 4% (P < 0.0005) the following year, with decrease in admission days from 54 to 18 per 100 patient years (P < 0.0005). In the same period, work absenteeism decreased and QOL improved significantly, with strong decline in fear of hypoglycemia. Conclusion: Sensor-augmented pump therapy in patients with T1D followed in specialized centers improves HbA1c, fear of hypoglycemia, and QOL, whereas work absenteeism and admissions for acute diabetes complications decreased.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Benefits of CGM in this population include reductions in A1C, fewer severe hypoglycemia events in children and adults, increased TIR, as well as significant reductions in hospitalizations for severe hypoglycemia and DKA.156,162–168”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [165]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPSS survival manual : a step by step guide to data analysis using SPSS
Pallant, J. (2010) · Cited by 6,888
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069 · cited 1×
“statement (11), our trial reports on time in hypoglycemia, time in range, and glucose variability.”
BackgroundContinuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Assessment of Diabetes-Related Distress
Polonsky, W. H., Anderson, B. J., Lohrer, P. A., Welch, G., Jacobson, A. M., Aponte, J. E., & Schwartz, C. E. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.754 · Cited by 1,497
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Hex, N., Bartlett, C., Wright, D., Taylor, M., & Varley, D. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03698.x · Cited by 819 · cited 1×
“Of interest, we also observed a decline in work absenteeism, which is a less visible (but substantial) financial burden to society (22).”
BackgroundFear of hypoglycemia: quantification, validation, and utilization
Cox, D. J., Irvine, A., Gonder-Frederick, L., Nowacek, G., & Butterfield, J. (1987) · Diabetes Care · doi:10.2337/diacare.10.5.617 · Cited by 579 · cited 1×
“All questionnaires [SF-36 (12), Problem Areas in Diabetes-short form (13–15), andHypoglycemia Fear Survey (HFS)-Worry (16, 17)] were validated in both Belgian languages (Dutch and French) and presented to patients in their mother tongue (Supplemental Table 2).”
Backgroundthe SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
McGuire, B. E., Morrison, T. G., Hermanns, N., Skovlund, S., Eldrup, E., Gagliardino, J., Kokoszka, A., Matthews, D., Pibernik-Okanović, M., Rodríguez-Saldaña, J., et al. (2010) · Diabetologia · doi:10.1007/s00125-009-1559-5 · Cited by 424 · cited 1×
“Additionally, almost half of the patients in the RESCUE trial reported problematic emotional distress (15).”
BackgroundPsychometric properties of the hypoglycemia fear survey-ii for adults with type 1 diabetes
Gonder-Frederick, L. A., Schmidt, K. M., Vajda, K. A., Greear, M. L., Singh, H., Shepard, J. A., & Cox, D. J. (2011) · Diabetes Care · doi:10.2337/dc10-1343 · Cited by 337
Research works printed but not linked: 1
- Ware, 1993, SF-36 Health Survey: Manual and Interpretation Guide
Cited by
Items 101–196 of 196
Aernouts, C., Beldé, S. P. W., Lambrechts, J., Mertens, J., Ledeganck, K. J., Francque, S., & Block, C. E. M. D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15723 · Cited by 13
Mustonen, J., Rautiainen, P., Lamidi, M., Lavikainen, P., Martikainen, J. A., & Laatikainen, T. K. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02079-y · Cited by 14
“Real-world studies also suggest lower rates of DKA after initiation of rtCGM [8] or isCGM [9, 10].”
BackgroundMessaaoui, A., Tenoutasse, S., Hajselova, L., & Crenier, L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01297-x · Cited by 9
Self-citationKant, R., Antony, M. A., Geurkink, D. W., Gilreath, N., Chandra, L., Zipprer, E., Munir, K. M., Chandra, R., Parker, V. G., & Verma, V. K. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.09.005 · Cited by 10
Reyes‐García, R., Mezquita‐Raya, P., Moreno, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Pardo, R. M., Jódar-Gimeno, E., Escalada, J., Gargallo-Fernández, M., Soto-González, A., et al. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2020.08.007 · Cited by 9
Flash glucose monitoring and glycemic control in type 1 diabetes with subcutaneous insulin infusion
Pinheiro, S. L., Bastos, M., Barros, L. M., Melo, M., & Paiva, I. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01827-2 · Cited by 9
Viñals, C., Quirós, C., Giménez, M., & Conget, I. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0599-1 · Cited by 9
Levy, C. J., Galindo, R. J., Parkin, C. G., Gillis, J., & Argento, N. B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231161317 · Cited by 13
Ko, J., Moon, S., Ajjan, R. A., Lee, M. Y., Lee, H., Choi, B., Park, J., Lee, S., Kang, J., & Park, C. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16304 · Cited by 7
“Given that the work-place has many self-management challenges, 28 and that CGM use can reduce diabetes-related absenteeism, fear of hypoglycaemia and social stigma, workplace-based interventions using CGM may have substantial benefits among workers with T2D.”
Reddy, S., Wu, C. C., José, A. S., Hsieh, J. L., & Rautela, S. D. (2023) · Clinical Diabetes · doi:10.2337/cd22-0128 · Cited by 8
Insurance Coverage for Emerging Diabetes Technologies: Payers' Perspective
Nolan, T., & Frazzitta, M. A. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0262 · Cited by 6
Practical Application of Continuous Glucose Monitoring in Clinical Practice: Case Studies
Unger, J., & Franco, D. R. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0080 · Cited by 7
Jensch, H., Setford, S. J., Thomé, N., Srikanthamoorthy, G., Weingärtner, L., Grady, M., Holt, E., & Pfützner, A. (2025) · Sensors · doi:10.3390/s25071985 · Cited by 10
Miller, E. M., Roberts, G. J., Joseph, J., Nabutovsky, Y., Reyes, I. J., Souto, D., Virdi, N. S., & Hirsch, I. B. (2022) · American Journal of Medicine Open · doi:10.1016/j.ajmo.2022.100008 · Cited by 7
Molfetta, S. D., Rossi, A., Gesuita, R., Faragalli, A., Cutruzzolà, A., Irace, C., Minuto, N., Pitocco, D., Cardella, F., Arnaldi, C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02381-3 · Cited by 6
Hayek, A. A., Mashali, M. A., & Dawish, M. A. A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01569-w · Cited by 7
Gómez, P. R. D. V., Jiménez, B. R., Sánchez, E. M., Sánchez, F. J., García, R. R., Umpierrez, G. E., & Martínez‐Brocca, M. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112372 · Cited by 8
Takai, T., Okada, Y., Takebe, R., & Nakamura, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00539-w · Cited by 4
Insulinoma Unmasked: A Continuous Glucose Monitoring-Fueled Journey
Koceva, A., & Krajnc, M. (2024) · Current Oncology · doi:10.3390/curroncol31090403 · Cited by 5
Pfützner, A., Tencer, B., Stamm, B., Mehta, M., Sharma, P., Gilyazev, R., Jensch, H., Thomé, N., & Huth, M. (2023) · Sensors · doi:10.3390/s23094541 · Cited by 5
Visser, M. M., Muylder, A. V., Charleer, S., Isitt, J. J., Roze, S., Block, C. E. M. D., Maes, T., Vanhaverbeke, G., Nobels, F. R. E., Keymeulen, B., et al. (2024) · Diabetologia · doi:10.1007/s00125-023-06084-2 · Cited by 6
“Previous studies have already demonstrated a decrease in work absenteeism with the use of CGM in type 1 diabetes [43, 44].”
Self-citationReyes‐García, R., Mezquita‐Raya, P., Moreno-Pérez, Ó., Muñoz‐Torres, M., Merino-Torres, J. F., Pardo, R. M., Jódar-Gimeno, E., Martín, J. E. S., Gargallo-Fernández, M., Soto-González, A., et al. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.06.004 · Cited by 6
Continuous and Flash Glucose Monitoring in Adults at Risk of Type 2 Diabetes: A Scoping Review
Amoh, P., Broom, D. R., Kyrou, I., Nartey, S., Paul, A., Esliger, D., & Whelan, M. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251315497 · Cited by 5
“27,30 This scoping review identified 12 studies on the use of the technology in individuals at T2DM risk, conducted primarily in high-income countries, such as the United States and the United Kingdom, which have a well-established track record in health care innovation and digital health…”
Jeter, K. M., Fisher, R. S., Traino, K. A., Dattilo, T., Allen, R. A., Anderson, M. P., Cutler, J., Sparling, D. P., & Beck, J. K. (2025) · Psychology Health & Medicine · doi:10.1080/13548506.2025.2575402 · Cited by 4
An electrochemical continuous glucose monitoring sensor utilizing ferrocene-derivative as a mediator
Nayak, K. K., Dorai, V. K., Pradhan, R. K., Jhunjhunwala, S., & Bhat, N. (2025) · Microchemical Journal · doi:10.1016/j.microc.2025.113795 · Cited by 4
Nayak, K. K., & Bhat, N. (2024) · IEEE Sensors Journal · doi:10.1109/jsen.2024.3449388 · Cited by 5
“Continuous glucose monitors (CGMs) have offered an efficient way to manage diabetes, reducing the events of hypoglycemia and diabetes-related hospitalizations while improving glycemic control, as indicated by multiple studies [5], [6], [7], [8].”
BackgroundNeue Therapieoptionen mit kontinuierlich gemessenen Glukosedaten – Empfehlungen für die Praxis
Seufert, J., Deiss, D., Gölz, S., Haak, T., Klausmann, G., Kroeger, J., Lobmann, R., Pfeiffer, A. F. H., Schnell, O., Seibold, A., et al. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-0978-4537 · Cited by 4
“[29] Charleer S, Mathieu C, Nobels F et al.”
BackgroundHohendorff, J., Czupryniak, L., Dzida, G. J., Fichna, P., Jarosz-Chobot, P. A., Klupa, T., Myśliwiec, M., Szadkowska, A., Zozulińska‐Ziółkiewicz, D., & Malecki, M. T. (2021) · Archives of Medical Science · doi:10.5114/aoms/139025 · Cited by 10
“Preventing severe episodes of hypoglycaemia or hyperglycaemia can also reduce the incidence of hospitalisation of diabetes patients [37].”
BackgroundHurteau, L. B., & Hogue, N. J. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.550 · Cited by 7
Franco, L., Bozzetto, L., Angelis, R. D., Calabrese, I., Cavagnuolo, L., Gasparro, T., Riccardi, G., Rivellese, A. A., & Annuzzi, G. (2021) · Health Science Reports · doi:10.1002/hsr2.385 · Cited by 4
“In addition, insulin pump therapy and continuous glucose monitoring (CGM) have proven to be valuable aids, showing advantages in terms of glycemic compensation, risk of hypoglycemia, and quality of life.(4,5)”
BackgroundGuideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
Behnke, A., Lucas, K. S., Parkin, C. G., Reddy, V., Orlowski, M., & Edwards, A. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0085 · Cited by 3
Diabetes mellitus and work participation
Tomic, D., Walker-Bone, K. E., Keegel, T. G., Zomer, E., Zoungas, S., & Magliano, D. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01194-w · Cited by 7
“CGM reduces self-care burden and hypoglycaemia risk 96,97 , but its long-term effect on work remains underexplored.”
Briganti, S., Lanza, O., Renzelli, V., Campagna, G., Maggi, D., Caprio, M., Manfrini, S., & Strollo, R. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109215 · Cited by 3
Effects of Sterilization on Cellobiose Dehydrogenase and Glucose Oxidase Based Glucose Biosensors
Bennett, R., Rathore, A., Gounel, S., Lielpētere, A., Reichhart, T. M. B., Jayakumar, K., Ludwig, R., Felice, A. K. G., Leech, D., Schuhmann, W. W., et al. (2024) · Advanced Sensor Research · doi:10.1002/adsr.202400056 · Cited by 3
Maintaining and sustaining a telehealth-based ecosystem
John, O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814309-4.00007-0 · Cited by 3
Vallarino, C. R., Wong-Jacobson, S., Benneyworth, B. D., & Meadows, E. S. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211052081 · Cited by 4
Continuous Glucose Monitoring Efficacy in Routine Use
Battelino, T. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00275 · Cited by 3
Use of Retrospective Continuous Glucose Monitoring Data Is Underrated and Underused
Nguyen, Q., Iyyavoo, A. A., & Parkin, C. G. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211070837 · Cited by 4
Schweiger, D. Š., & Battelino, T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816714-4.00001-6 · Cited by 3
New technical approach to the diabetes therapy
Dovč, K., & Battelino, T. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05865-x · Cited by 3
Steenackers, N., Sparsø, T., Charleer, S., Block, C. E. M. D., Cock, D. D., Delfin, C., Mathieu, C., Nobels, F. R. E., Pazmiño, S., Rosen, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15886 · Cited by 2
“A few studies have investigated the link between health-related quality of life in people with type 1 diabetes and glycaemic control, 18,19 or new treatments, 20 but they did not relate quality-of-life scores to findings in the overall population.”
Self-citationSoto-Hernaez, J., McCrimmon, R. J., Pearson, E. R., & Soto‐Pedre, E. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109089 · Cited by 2
Satisfaction with life in young adults with type 1 diabetes mellitus
Stefanowicz, A., Rąpała, M., Mazuryk, K., Kawa, M., & Dygaszewicz, E. (2025) · Scientific Reports · doi:10.1038/s41598-025-07675-2 · Cited by 3
Health-Care Disparities in the Use of Diabetes Technologies in the UK
Barnard-Kelly, K. D., & Parkin, C. G. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_1_23 · Cited by 3
Beck, J. K., Allen, R. A., Jeter, K. M., Fisher, R. S., Dattilo, T. M., Traino, K. A., Anderson, M. P., Cutler, J., & Sparling, D. P. (2023) · Pediatric Diabetes · doi:10.1155/2023/5253515 · Cited by 2
Redel, J. M., Hornung, L. N., Elder, D. A., Nathan, J. D., Corathers, S. D., Rich, K. L., & Abu‐El‐Haija, M. A. (2023) · Pediatric Diabetes · doi:10.1155/2023/2851620 · Cited by 2
Recomendaciones para la práctica clínica: hipoglucemia en personas con diabetes mellitus
Martín, C. G., Loredo, S. D., Forlino, M., Rodríguez, A., Ré, M., Santos, N. C. G., Dimov, L., Apoloni, S. B., Remón, J., Ávila, P. J., et al. (2022) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v56i2sup.539 · Cited by 3
Hernandez‐Calderon, A., Gonzalvo, J. D., Triboletti, J. S., Walroth, T. A., Lewis, S. P., & Pence, L. M. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70007 · Cited by 2
Psychosocial aspects of the usage of modern technologies in diabetes mellitus
Мотовилин, О. Г., Surkova, E. V., Самвеловна, Б. А., Ibragimova, L. I., & Mayorov, A. Y. (2019) · Diabetes Mellitus · doi:10.14341/dm9972 · Cited by 2
Lazar, D., Tao, M., Matievich, W., Kastanos, K., & Dunn, T. C. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241260038 · Cited by 1
Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium
Theys, K., Vermander, S., Annemans, L., Block, C. E. M. D., Hermans, M. P., Matthys, I., Nobels, F. R. E., Nguyen, T. T., Preumont, V., Zakrzewska, K. E., et al. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00547-x · Cited by 2
“Costs associated with an event requiring hospitalization for PwD with T1DM were reported in the RESCUE study [28] for 2018, while the respective cost for PwD with T2DM was estimated using the T1DM/T2DM cost ratio of severe events.”
Self-citationLogothetis, G., Avramidis, K., Konstantaki, E., Matziou, V. N., & Doupis, J. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.7 · Cited by 1
Muller, N., Kellner, C., Schmidt, S., Kuniß, N., Wolf, G., & Kloos, C. (2025) · Diabetic Medicine · doi:10.1111/dme.70121 · Cited by 1
“CGM can reduce the fear of hypoglycaemia and improve quality of life in participants with type 1 diabetes without and with IAH 24,25 whereas in participants with type 2 diabetes the evidence is not clear, probably due to the lower frequency of hypoglycaemia in these participants.”
Giacinto, A. M. D., Petrosino, L., D’Antoni, F., Marchetti, A., Vollero, L., Pecchia, L., & Merone, M. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.109037 · Cited by 2
Cui, Y., & Li, P. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119115 · Cited by 1
Boudreau, E. C., Rastegar, J. S., Swankoski, K. E., Hames, A., Mugavin, M. O., & Ross, J. S. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.3.329 · Cited by 1
Richardson, E., Stribling, B., Ridgeway, J., Kitching‐Davis, C., Willcocks, L., Heggs, L., Wakefield, H., Gallen, G., Jolley, A., Bareford, K., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70253 · Cited by 1
Sabbe, A. C. F., Bochanen, N., den Broucke, A. V., Mihaljčić, K., Bigaré, A., Dessel, K. V., Bouziotis, J., Ledeganck, K. J., Dirinck, E. L., Bolsens, N., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag380
Self-citationUpdate on recent advances in technology in type 1 diabetes
Aslam, A., Thabit, H., & Leelarathna, L. (2024) · British Journal of Diabetes · doi:10.15277/bjd.2024.440 · Cited by 2
Continuous Glucose Monitoring in Individuals With Type 2 Diabetes: A Quality Improvement Program
Kinson, L., & Inman, K. (2024) · Clinical Diabetes · doi:10.2337/cd24-0006 · Cited by 5
Dynamic Interference Testing Results with the Dexcom G6 Continuous Glucose Monitoring Device
Thomé, N., Jensch, H., Srikanthamoorthy, G., Weingärtner, L., Grady, M., Setford, S. J., Holt, E., & Pfützner, A. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2024.0009 · Cited by 1
Steenkamp, D. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0100 · Cited by 1
Yamamoto, J. M., & Murphy, H. R. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2508 · Cited by 1
“Data from Belgium provide some insights into the ‘‘real-word’’ use of CGM in insulin pump users use before and during pregnancy (6).”
Safety and Performance of Continuous Glucose Monitoring: An Overview
Venkatesan, V., & Singh, H. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220525111746 · Cited by 2
van Dijk, P. R., Lommerde, N., Fokkert, M. J., Edens, M. A., Hernández, A. D., Delgado, E., Slingerland, R. J., & Bilo, H. J. G. (2022) · Research Square · doi:10.21203/rs.3.rs-1319932/v1 · Cited by 1
Hidden in the Night: Wearable Sleep Assessment of Nocturnal Hypoglycaemia in Type 1 DiabetesPreprint
Alsuhaymi, A., Nutter, P. W., Thabit, H., & Harper, S. (2026) · medRxiv · doi:10.64898/2026.01.22.26344161 · Cited by 1
Continuous Glucose Monitors are Cost Neutral Compared to SMBG
Elliott, T. G., & Weissinger, A. (2020) · Journal of Diabetes Research and Therapy · doi:10.16966/2380-5544.155
“[3] found that savings are also expected to be achieved by a reduction in the frequency of Diabetic Ketoacidosis (DKA).”
BackgroundInfluentialContinuous and Intermittent Glucose Monitoring in 2020
Bode, B. W., Battelino, T., & Dovč, K. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.2502
“Following the success of the Belgian CGM-CSII real-world study (29) and its continuation—the RESCUE trial (30), where, similarly to the previously discussed SILVER study, a sustained benefit of real-time CGM is demonstrated over 24 months—this FUTURE trial shows the efficacy of isCGM along with…”
Alhodaib, H. I., & Alsulihem, S. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i11.1908
Clinical and economic benefits of continuous blood glucose monitoring devices
Rahman, R. S., Salamah, H. E., Alshair, F. M., Alsawadi, A. A., Alghamdi, O. M., Alalasi, A. B., Mufarrihi, A. M., Alalawi, A. O., Alzahrani, O. M., Alanazi, H. O., et al. (2022) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20220053
“In addition, another investigation that included patients with T1DM who began to use CGM devices showed that work absenteeism, hospital stay, and hospitalization due to ketoacidosis and/or hypoglycemia was significantly reduced during one year of follow-up.(19) However, among”
BackgroundGlucose Monitoring and Sensing
Pickup, J. C., & Oliver, N. S. (2022) · doi:10.1093/med/9780198870197.003.0251
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814309-4.09998-5
Cherubini, V. (2020) · Springer eBooks · doi:10.1007/978-3-030-42806-8_11
Paradigmenwechsel in der Glukosekontrolle: Urin-, Blut-, interstitielle Glukosemessung
Forst, T. M. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1225-8678
Kröger, J. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00941-1
“In der RESCUE-Studie [38] war der Einsatz von rt-CGMbeiMenschenmit Typ 1Diabetes und einer Insulinpumpentherapie mit einem deutlichen Rückgang der Zahl der Teilnehmer mit schweren Hypoglykämien und Krankenhausaufenthalten aufgrund einer diabetischen Ketoazidose verbunden, und zwar von 11, 9% auf 3,17% bzw. von 4,6% au…”
BackgroundAssessment of accuracy and glycemic control of FGM and CGM and impact on mental well-being
Gesslbauer, M., Koehler, G., Baumgärtner, C., & Šajić, J. L. (2022) · Current Directions in Biomedical Engineering · doi:10.1515/cdbme-2022-1002
Wu, C., Wu, K. C., & Reddy, S. (2023) · doi:10.2196/preprints.49925
Editorial: Daily challenges around physical exercise, nutrition and medication in type 1 diabetes
Moser, O., & Dovč, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1259535
Lameijer, A. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1021051970
Owaydah, A., Abouglila, K., & Liloglou, T. (2024) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.1055/s-0044-1787111
李, 康. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.34367
Continuous Glucose Monitoring for Inpatients on Intravenous Insulin
GOOD, K. L., Joshi, R., & SNELL, V. M. (2025) · Clinical Nurse Specialist · doi:10.1097/nur.0000000000000888
Wu, C. C., Wu, K. C., & Reddy, S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0005
Asebiga, C. A., Bam, V. B., & Lomotey, A. Y. (2025) · BMC Public Health · doi:10.1186/s12889-025-25778-3
“Existing literature often focuses on individuals with long-term diabetes [28–32], leaving a gap regarding those newly diagnosed individuals.”
Wang, R., Kyi, M., Krishnamoorthi, B., Connell, A., Chiang, C. Y., Renouf, D., Barmanray, R., & Fourlanos, S. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251395088
Insulin in Its Second Century: History, Evolution, and Aspirations
Mayer, J. P., Thalluri, K., Mickelson, E., Stowell, M. H. B., & DiMarchi, R. D. (2025) · Peptide Science · doi:10.1002/9781119824701.ch08
Characteristics, Risk Factors, and Outcome of Recurrent Diabetic Ketoacidosis in Adults
Eledrisi, M. S., ALKABBANI, H. M., ABOAWON, M. K., ALI, A. A., Alabdulrazzak, I., Elhaj, M. F., Ahmed, A., Alqahwachi, H., Daghfal, J., Beshyah, S., et al. (2026) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0046-1818535
Šuminienė, J., Stukas, R., Gaigalaitė, V., Kriaučiūnienė, D., & Istomina, N. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1708124
Dovč, K., Mianowska, B., Boettcher, C., Cardona‐Hernandez, R., Berge, T. V. D., Davis, E. A., Kosteria, I., Marigliano, M., Rami-Merhar, B. M., Scharf, M., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261463841
Lavens, A., Philips, J., Block, C. E. M. D., Crenier, L., Oriot, P., Vandenbroucke, M., Tenoutasse, S., den Brinker, M., Aken, S. V., Nobels, F. R. E., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261464233
Self-citationValgaerts, L., Meulemeester, J. D., Visser, M. M., Charleer, S., Fieuws, S., Keymeulen, B., Block, C. E. M. D., Mathieu, C., Casteels, K., & Gillard, P. (2026) · Diabetes Care · doi:10.2337/dc26-0763 · Cited by 1
Self-citationManaging Gestational Diabetes Complexity with Continuous Glucose Monitoring: A Narrative Review
Craciun, A. E., Ciobanu, D. M., Inceu, G., Vonica, C. L., Herman, D., Crăciun, C.-I., Fodor, A., Bala, C. G., & Rusu, A. (2026) · Diagnostics · doi:10.3390/diagnostics16142145
“In a cohort study including pregnant women with T1D, although 90% of participants continued real-time CGM after six months, discontinuation in some cases was attributed to system-related stress, psychiatric comorbidities, or termination of reimbursement following delivery [134].”
Pazmiño, S., Schmid, S., Steenackers, N., Sandig, R., van Laar, A., Weiskorn, J., Meulemeester, J. D., Mader, J. K., Charleer, S., Wosch, F. J., et al. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101806
“Further details about the data sources and eligibility criteria have been previously published 18–21 and can also be found in Supplementary Material.”
Self-citationStraathof, S., Tadema, M. J., Zhan, L., & Maglia, G. (2026) · ACS Nano · doi:10.1021/acsnano.6c10533
Roadmap to Fully Closing the Loop to Optimize Health in Type 1 Diabetes
Marks, B. E., Hilliard, M. E., Kovatchev, B. P., Moser, O., Tanenbaum, M. L., Ackeifi, C. A., Ahn, D. T., Ajjan, R., Albanese-O’Neill, A., BAKHSH, A. M. K., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261496643
Self-citation
Metadata
- Authors
- Charleer, S., Mathieu, C., Nobels, F., De Block, C., Radermecker, R. P., Hermans, M. P., Taes, Y., Vercammen, C., T'Sjoen, G., Crenier, L., Fieuws, S., Keymeulen, B., Gillard, P., & RESCUE Trial Investigators
- Affiliations
- Research Foundation - Flanders (BE)
- KU Leuven (BE)
- Onze Lieve Vrouwziekenhuis Hospital (BE)
- Department of Endocrinology, Diabetology and Metabolism, University of Antwerp–Antwerp University Hospital, Antwerp, Belgium
- Department of Diabetes, Nutrition and Metabolic Disorders, Centre Hospitalier Universitaire Liege–Liege University, Liege, Belgium
- Cliniques Universitaires Saint-Luc (BE)
- AZ Sint-Jan (BE)
- Imelda Hospital (BE)
- Ghent University Hospital (BE)
- Université Libre de Bruxelles (BE)
- Hasselt University (BE)
- Vrije Universiteit Brussel (BE)
- Corresponding author
- Gillard, Pieter
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-01-12
- Volume
- 103
- Issue
- 3
- Pages
- 1224-1232
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791573153
- Cited by
- 196
- References
- 29
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 23 · 2023: 22 · 2022: 27 · 2021: 39 · 2020: 15 · 2019: 22 · 2018: 11
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Lirias (submittedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek (10.13039/501100003130, http://dx.doi.org/10.13039/501100003130, 1S13517N, 501100003130)
- Vlaamse regering
- Horizon 2020 Framework Programme
- Universitaire Ziekenhuizen Leuven, KU Leuven
- H2020 European Institute of Innovation and Technology (http://dx.doi.org/10.13039/100010686)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, type 1 diabetes, glycemic control, HbA1c, hospitalization, absenteeism, quality of life, fear of hypoglycemia, insulin pump therapy, sensor-augmented pump therapy, hypoglycemia, diabetic ketoacidosis
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Hospitalization, Humans, Hypoglycemia, Male, Middle Aged, Prospective Studies, Quality of Life, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.